Ofatumumab  ||| S:0 E:11 ||| NNP
for  ||| S:11 E:15 ||| IN
the  ||| S:15 E:19 ||| DT
treatment  ||| S:19 E:29 ||| NN
of  ||| S:29 E:32 ||| IN
chronic  ||| S:32 E:40 ||| JJ
lymphocytic  ||| S:40 E:52 ||| JJ
leukaemia  ||| S:52 E:62 ||| NN
in  ||| S:62 E:65 ||| IN
patients  ||| S:65 E:74 ||| NNS
who  ||| S:74 E:78 ||| WP
are  ||| S:78 E:82 ||| VBP
refractory  ||| S:82 E:93 ||| VBN
to  ||| S:93 E:96 ||| TO
fludarabine  ||| S:96 E:108 ||| VB
and  ||| S:108 E:112 ||| CC
alemtuzumab ||| S:112 E:123 ||| NNS
:  ||| S:123 E:125 ||| :
a  ||| S:125 E:127 ||| DT
critique  ||| S:127 E:136 ||| NN
of  ||| S:136 E:139 ||| IN
the  ||| S:139 E:143 ||| DT
submission  ||| S:143 E:154 ||| NN
from  ||| S:154 E:159 ||| IN
GSK  ||| S:159 E:163 ||| NNP
This  ||| S:163 E:168 ||| DT
paper  ||| S:168 E:174 ||| NN
presents  ||| S:174 E:183 ||| VBZ
a  ||| S:183 E:185 ||| DT
summary  ||| S:185 E:193 ||| NN
of  ||| S:193 E:196 ||| IN
the  ||| S:196 E:200 ||| DT
evidence  ||| S:200 E:209 ||| NN
review  ||| S:209 E:216 ||| NN
group  ||| S:216 E:222 ||| NN
( ||| S:222 E:223 ||| -LRB-
ERG ||| S:223 E:226 ||| NNP
)  ||| S:226 E:228 ||| -RRB-
report  ||| S:228 E:235 ||| NN
into  ||| S:235 E:240 ||| IN
the  ||| S:240 E:244 ||| DT
clinical  ||| S:244 E:253 ||| JJ
effectiveness  ||| S:253 E:267 ||| NN
and  ||| S:267 E:271 ||| CC
cost-effectiveness  ||| S:271 E:290 ||| JJ
of  ||| S:290 E:293 ||| IN
ofatumumab  ||| S:293 E:304 ||| NN
for  ||| S:304 E:308 ||| IN
the  ||| S:308 E:312 ||| DT
treatment  ||| S:312 E:322 ||| NN
of  ||| S:322 E:325 ||| IN
refractory  ||| S:325 E:336 ||| FW
chronic  ||| S:336 E:344 ||| FW
lymphocytic  ||| S:344 E:356 ||| FW
leukaemia  ||| S:356 E:366 ||| FW
( ||| S:366 E:367 ||| -LRB-
CLL ||| S:367 E:370 ||| NNP
) ||| S:370 E:371 ||| -RRB-
,  ||| S:371 E:373 ||| ,
based  ||| S:373 E:379 ||| VBN
upon  ||| S:379 E:384 ||| IN
the  ||| S:384 E:388 ||| DT
manufacturer ||| S:388 E:400 ||| NN
's  ||| S:400 E:403 ||| POS
submission  ||| S:403 E:414 ||| NN
( ||| S:414 E:415 ||| -LRB-
MS ||| S:415 E:417 ||| NNP
)  ||| S:417 E:419 ||| -RRB-
to  ||| S:419 E:422 ||| TO
the  ||| S:422 E:426 ||| DT
National  ||| S:426 E:435 ||| NNP
Institute  ||| S:435 E:445 ||| NNP
for  ||| S:445 E:449 ||| IN
Health  ||| S:449 E:456 ||| NNP
and  ||| S:456 E:460 ||| CC
Clinical  ||| S:460 E:469 ||| NNP
Excellence  ||| S:469 E:480 ||| NNP
( ||| S:480 E:481 ||| -LRB-
NICE ||| S:481 E:485 ||| NNP
)  ||| S:485 E:487 ||| -RRB-
as  ||| S:487 E:490 ||| IN
part  ||| S:490 E:495 ||| NN
of  ||| S:495 E:498 ||| IN
the  ||| S:498 E:502 ||| DT
single  ||| S:502 E:509 ||| JJ
technology  ||| S:509 E:520 ||| NN
appraisal  ||| S:520 E:530 ||| NN
process ||| S:530 E:537 ||| NN
.  ||| S:537 E:539 ||| .
The  ||| S:539 E:543 ||| DT
submitted  ||| S:543 E:553 ||| VBN
clinical  ||| S:553 E:562 ||| JJ
evidence  ||| S:562 E:571 ||| NN
included  ||| S:571 E:580 ||| VBD
one  ||| S:580 E:584 ||| CD
study ||| S:584 E:589 ||| NN
:  ||| S:589 E:591 ||| :
a  ||| S:591 E:593 ||| DT
non-randomised ||| S:593 E:607 ||| JJ
,  ||| S:607 E:609 ||| ,
single-arm  ||| S:609 E:620 ||| JJ
study ||| S:620 E:625 ||| NN
.  ||| S:625 E:627 ||| .
Two  ||| S:627 E:631 ||| CD
other  ||| S:631 E:637 ||| JJ
studies  ||| S:637 E:645 ||| NNS
were  ||| S:645 E:650 ||| VBD
identified  ||| S:650 E:661 ||| VBN
but  ||| S:661 E:665 ||| CC
both  ||| S:665 E:670 ||| DT
were  ||| S:670 E:675 ||| VBD
non-comparative  ||| S:675 E:691 ||| JJ
and  ||| S:691 E:695 ||| CC
provided  ||| S:695 E:704 ||| VBN
evidence  ||| S:704 E:713 ||| NN
for  ||| S:713 E:717 ||| IN
therapies  ||| S:717 E:727 ||| JJ
other  ||| S:727 E:733 ||| JJ
than  ||| S:733 E:738 ||| IN
ofatumumab ||| S:738 E:748 ||| NN
.  ||| S:748 E:750 ||| .
For  ||| S:750 E:754 ||| IN
this  ||| S:754 E:759 ||| DT
reason  ||| S:759 E:766 ||| NN
these  ||| S:766 E:772 ||| DT
studies  ||| S:772 E:780 ||| NNS
were  ||| S:780 E:785 ||| VBD
not  ||| S:785 E:789 ||| RB
discussed  ||| S:789 E:799 ||| VBN
in  ||| S:799 E:802 ||| IN
full  ||| S:802 E:807 ||| JJ
in  ||| S:807 E:810 ||| IN
the  ||| S:810 E:814 ||| DT
main  ||| S:814 E:819 ||| JJ
body  ||| S:819 E:824 ||| NN
of  ||| S:824 E:827 ||| IN
the  ||| S:827 E:831 ||| DT
submission ||| S:831 E:841 ||| NN
.  ||| S:841 E:843 ||| .
In  ||| S:843 E:846 ||| IN
the  ||| S:846 E:850 ||| DT
Hx-CD20-406  ||| S:850 E:862 ||| JJ
study ||| S:862 E:867 ||| NN
,  ||| S:867 E:869 ||| ,
the  ||| S:869 E:873 ||| DT
overall  ||| S:873 E:881 ||| JJ
response  ||| S:881 E:890 ||| NN
rate  ||| S:890 E:895 ||| NN
was  ||| S:895 E:899 ||| VBD
58 ||| S:899 E:901 ||| CD
%  ||| S:901 E:903 ||| NN
( ||| S:903 E:904 ||| -LRB-
99 ||| S:904 E:906 ||| CD
%  ||| S:906 E:908 ||| NN
confidence  ||| S:908 E:919 ||| NN
interval  ||| S:919 E:928 ||| VBD
40 ||| S:928 E:930 ||| CD
%  ||| S:930 E:932 ||| NN
to  ||| S:932 E:935 ||| TO
74 ||| S:935 E:937 ||| CD
% ||| S:937 E:938 ||| NN
,  ||| S:938 E:940 ||| ,
p  ||| S:940 E:942 ||| CD
< ||| S:942 E:944 ||| SYM
0.001 ||| S:944 E:949 ||| CD
) ||| S:949 E:950 ||| -RRB-
.  ||| S:950 E:952 ||| .
Complete  ||| S:952 E:961 ||| JJ
resolution  ||| S:961 E:972 ||| NN
of  ||| S:972 E:975 ||| IN
constitutional  ||| S:975 E:990 ||| JJ
symptoms  ||| S:990 E:999 ||| NNS
and  ||| S:999 E:1003 ||| CC
improved  ||| S:1003 E:1012 ||| JJ
performance  ||| S:1012 E:1024 ||| NN
status  ||| S:1024 E:1031 ||| NN
occurred  ||| S:1031 E:1040 ||| VBD
in  ||| S:1040 E:1043 ||| IN
57 ||| S:1043 E:1045 ||| CD
%  ||| S:1045 E:1047 ||| NN
of  ||| S:1047 E:1050 ||| IN
patients ||| S:1050 E:1058 ||| NNS
.  ||| S:1058 E:1060 ||| .
Median  ||| S:1060 E:1067 ||| JJ
progression-free  ||| S:1067 E:1084 ||| JJ
survival  ||| S:1084 E:1093 ||| NN
( ||| S:1093 E:1094 ||| -LRB-
PFS ||| S:1094 E:1097 ||| NNP
)  ||| S:1097 E:1099 ||| -RRB-
and  ||| S:1099 E:1103 ||| CC
overall  ||| S:1103 E:1111 ||| JJ
survival  ||| S:1111 E:1120 ||| NN
( ||| S:1120 E:1121 ||| -LRB-
OS ||| S:1121 E:1123 ||| NNP
)  ||| S:1123 E:1125 ||| -RRB-
times  ||| S:1125 E:1131 ||| NNS
were  ||| S:1131 E:1136 ||| VBD
5.7  ||| S:1136 E:1140 ||| CD
and  ||| S:1140 E:1144 ||| CC
13.7  ||| S:1144 E:1149 ||| CD
months ||| S:1149 E:1155 ||| NNS
,  ||| S:1155 E:1157 ||| ,
respectively ||| S:1157 E:1169 ||| RB
.  ||| S:1169 E:1171 ||| .
The  ||| S:1171 E:1175 ||| DT
most  ||| S:1175 E:1180 ||| RBS
common  ||| S:1180 E:1187 ||| JJ
adverse  ||| S:1187 E:1195 ||| JJ
events  ||| S:1195 E:1202 ||| NNS
during  ||| S:1202 E:1209 ||| IN
treatment  ||| S:1209 E:1219 ||| NN
were  ||| S:1219 E:1224 ||| VBD
infusion  ||| S:1224 E:1233 ||| JJ
reactions  ||| S:1233 E:1243 ||| NNS
and  ||| S:1243 E:1247 ||| CC
infections ||| S:1247 E:1257 ||| NNS
,  ||| S:1257 E:1259 ||| ,
which  ||| S:1259 E:1265 ||| WDT
were  ||| S:1265 E:1270 ||| VBD
primarily  ||| S:1270 E:1280 ||| RB
grade  ||| S:1280 E:1286 ||| CD
1  ||| S:1286 E:1288 ||| CD
or  ||| S:1288 E:1291 ||| CC
2  ||| S:1291 E:1293 ||| CD
events ||| S:1293 E:1299 ||| NNS
.  ||| S:1299 E:1301 ||| .
The  ||| S:1301 E:1305 ||| DT
MS  ||| S:1305 E:1308 ||| NNP
concluded  ||| S:1308 E:1318 ||| VBD
that  ||| S:1318 E:1323 ||| DT
ofatumumab  ||| S:1323 E:1334 ||| NN
provides  ||| S:1334 E:1343 ||| VBZ
a  ||| S:1343 E:1345 ||| DT
new ||| S:1345 E:1348 ||| JJ
,  ||| S:1348 E:1350 ||| ,
effective  ||| S:1350 E:1360 ||| JJ
and  ||| S:1360 E:1364 ||| CC
well-tolerated  ||| S:1364 E:1379 ||| JJ
therapy  ||| S:1379 E:1387 ||| NN
for  ||| S:1387 E:1391 ||| IN
patients  ||| S:1391 E:1400 ||| NNS
with  ||| S:1400 E:1405 ||| IN
CLL  ||| S:1405 E:1409 ||| NNP
who  ||| S:1409 E:1413 ||| WP
are  ||| S:1413 E:1417 ||| VBP
refractory  ||| S:1417 E:1428 ||| VBN
to  ||| S:1428 E:1431 ||| TO
both  ||| S:1431 E:1436 ||| DT
fludarabine  ||| S:1436 E:1448 ||| NN
and  ||| S:1448 E:1452 ||| CC
alemtuzumab  ||| S:1452 E:1464 ||| NNS
[ ||| S:1464 E:1465 ||| -LRB-
double  ||| S:1465 E:1472 ||| JJ
refractory  ||| S:1472 E:1483 ||| NNS
( ||| S:1483 E:1484 ||| -LRB-
DR ||| S:1484 E:1486 ||| NNP
) ||| S:1486 E:1487 ||| -RRB-
] ||| S:1487 E:1488 ||| -RRB-
.  ||| S:1488 E:1490 ||| .
The  ||| S:1490 E:1494 ||| DT
ERG  ||| S:1494 E:1498 ||| NNP
undertook  ||| S:1498 E:1508 ||| VBD
a  ||| S:1508 E:1510 ||| DT
critical  ||| S:1510 E:1519 ||| JJ
appraisal  ||| S:1519 E:1529 ||| NN
of  ||| S:1529 E:1532 ||| IN
the  ||| S:1532 E:1536 ||| DT
submission ||| S:1536 E:1546 ||| NN
.  ||| S:1546 E:1548 ||| .
The  ||| S:1548 E:1552 ||| DT
ERG  ||| S:1552 E:1556 ||| NNP
had  ||| S:1556 E:1560 ||| VBD
a  ||| S:1560 E:1562 ||| DT
number  ||| S:1562 E:1569 ||| NN
of  ||| S:1569 E:1572 ||| IN
concerns  ||| S:1572 E:1581 ||| NNS
regarding  ||| S:1581 E:1591 ||| VBG
the  ||| S:1591 E:1595 ||| DT
manufacturer ||| S:1595 E:1607 ||| NN
's  ||| S:1607 E:1610 ||| POS
estimates  ||| S:1610 E:1620 ||| NNS
of  ||| S:1620 E:1623 ||| IN
effectiveness  ||| S:1623 E:1637 ||| NN
based  ||| S:1637 E:1643 ||| VBN
on  ||| S:1643 E:1646 ||| IN
evidence  ||| S:1646 E:1655 ||| NN
from  ||| S:1655 E:1660 ||| IN
a  ||| S:1660 E:1662 ||| DT
single-arm ||| S:1662 E:1672 ||| JJ
,  ||| S:1672 E:1674 ||| ,
non-randomised  ||| S:1674 E:1689 ||| JJ
study ||| S:1689 E:1694 ||| NN
.  ||| S:1694 E:1696 ||| .
An  ||| S:1696 E:1699 ||| DT
' ||| S:1699 E:1700 ||| POS
area-under-the-curve ||| S:1700 E:1720 ||| NNP
'  ||| S:1720 E:1722 ||| POS
or  ||| S:1722 E:1725 ||| NN
' ||| S:1725 E:1726 ||| POS
partitioned-survival ||| S:1726 E:1746 ||| NNP
'  ||| S:1746 E:1748 ||| POS
model  ||| S:1748 E:1754 ||| NN
was  ||| S:1754 E:1758 ||| VBD
used  ||| S:1758 E:1763 ||| VBN
to  ||| S:1763 E:1766 ||| TO
project  ||| S:1766 E:1774 ||| VB
expected  ||| S:1774 E:1783 ||| VBN
clinical  ||| S:1783 E:1792 ||| JJ
and  ||| S:1792 E:1796 ||| CC
economic  ||| S:1796 E:1805 ||| JJ
outcomes  ||| S:1805 E:1814 ||| NNS
for  ||| S:1814 E:1818 ||| IN
patients  ||| S:1818 E:1827 ||| NNS
with  ||| S:1827 E:1832 ||| IN
DR  ||| S:1832 E:1835 ||| NNP
CLL  ||| S:1835 E:1839 ||| NNP
who  ||| S:1839 E:1843 ||| WP
were  ||| S:1843 E:1848 ||| VBD
assumed  ||| S:1848 E:1856 ||| VBN
to  ||| S:1856 E:1859 ||| TO
receive  ||| S:1859 E:1867 ||| VB
ofatumumab  ||| S:1867 E:1878 ||| NNS
or  ||| S:1878 E:1881 ||| CC
best  ||| S:1881 E:1886 ||| RBS
supportive  ||| S:1886 E:1897 ||| JJ
care  ||| S:1897 E:1902 ||| NN
( ||| S:1902 E:1903 ||| -LRB-
BSC ||| S:1903 E:1906 ||| NNP
) ||| S:1906 E:1907 ||| -RRB-
.  ||| S:1907 E:1909 ||| .
The  ||| S:1909 E:1913 ||| DT
model  ||| S:1913 E:1919 ||| NN
had  ||| S:1919 E:1923 ||| VBD
a  ||| S:1923 E:1925 ||| DT
three-state  ||| S:1925 E:1937 ||| JJ
structure ||| S:1937 E:1946 ||| NN
:  ||| S:1946 E:1948 ||| :
' ||| S:1948 E:1949 ||| ''
alive  ||| S:1949 E:1955 ||| JJ
pre-progression ||| S:1955 E:1970 ||| NN
' ||| S:1970 E:1971 ||| POS
,  ||| S:1971 E:1973 ||| ,
' ||| S:1973 E:1974 ||| ''
alive  ||| S:1974 E:1980 ||| JJ
post  ||| S:1980 E:1985 ||| NN
progression ||| S:1985 E:1996 ||| NN
'  ||| S:1996 E:1998 ||| POS
and  ||| S:1998 E:2002 ||| NN
' ||| S:2002 E:2003 ||| POS
dead ||| S:2003 E:2007 ||| NN
' ||| S:2007 E:2008 ||| POS
.  ||| S:2008 E:2010 ||| .
Overall ||| S:2010 E:2017 ||| RB
,  ||| S:2017 E:2019 ||| ,
the  ||| S:2019 E:2023 ||| DT
modelling  ||| S:2023 E:2033 ||| JJ
approach  ||| S:2033 E:2042 ||| NN
is  ||| S:2042 E:2045 ||| VBZ
reasonable  ||| S:2045 E:2056 ||| JJ
given  ||| S:2056 E:2062 ||| VBN
the  ||| S:2062 E:2066 ||| DT
limited  ||| S:2066 E:2074 ||| JJ
evidence  ||| S:2074 E:2083 ||| NN
available  ||| S:2083 E:2093 ||| JJ
for  ||| S:2093 E:2097 ||| IN
the  ||| S:2097 E:2101 ||| DT
drug  ||| S:2101 E:2106 ||| NN
in  ||| S:2106 E:2109 ||| IN
the  ||| S:2109 E:2113 ||| DT
patient  ||| S:2113 E:2121 ||| JJ
population  ||| S:2121 E:2132 ||| NN
under  ||| S:2132 E:2138 ||| IN
review ||| S:2138 E:2144 ||| NN
.  ||| S:2144 E:2146 ||| .
However ||| S:2146 E:2153 ||| RB
,  ||| S:2153 E:2155 ||| ,
a  ||| S:2155 E:2157 ||| DT
number  ||| S:2157 E:2164 ||| NN
of  ||| S:2164 E:2167 ||| IN
uncertainties  ||| S:2167 E:2181 ||| NNS
were  ||| S:2181 E:2186 ||| VBD
identified  ||| S:2186 E:2197 ||| VBN
in  ||| S:2197 E:2200 ||| IN
the  ||| S:2200 E:2204 ||| DT
economic  ||| S:2204 E:2213 ||| JJ
evaluation ||| S:2213 E:2223 ||| NN
;  ||| S:2223 E:2225 ||| :
for  ||| S:2225 E:2229 ||| IN
example ||| S:2229 E:2236 ||| NN
,  ||| S:2236 E:2238 ||| ,
the  ||| S:2238 E:2242 ||| DT
BSC  ||| S:2242 E:2246 ||| NNP
arm  ||| S:2246 E:2250 ||| NN
used  ||| S:2250 E:2255 ||| VBN
data  ||| S:2255 E:2260 ||| NNS
from  ||| S:2260 E:2265 ||| IN
patients  ||| S:2265 E:2274 ||| NNS
in  ||| S:2274 E:2277 ||| IN
the  ||| S:2277 E:2281 ||| DT
Hx-CD20-406  ||| S:2281 E:2293 ||| JJ
study  ||| S:2293 E:2299 ||| NN
who  ||| S:2299 E:2303 ||| WP
did  ||| S:2303 E:2307 ||| VBD
not  ||| S:2307 E:2311 ||| RB
respond  ||| S:2311 E:2319 ||| VB
to  ||| S:2319 E:2322 ||| TO
ofatumumab  ||| S:2322 E:2333 ||| VB
treatment  ||| S:2333 E:2343 ||| NN
-  ||| S:2343 E:2345 ||| :
' ||| S:2345 E:2346 ||| ''
non-responders ||| S:2346 E:2360 ||| JJ
'  ||| S:2360 E:2362 ||| ''
-  ||| S:2362 E:2364 ||| :
and  ||| S:2364 E:2368 ||| CC
the  ||| S:2368 E:2372 ||| DT
ofatumumab  ||| S:2372 E:2383 ||| JJ
arm  ||| S:2383 E:2387 ||| NN
used  ||| S:2387 E:2392 ||| VBN
data  ||| S:2392 E:2397 ||| NNS
from  ||| S:2397 E:2402 ||| IN
all  ||| S:2402 E:2406 ||| DT
of  ||| S:2406 E:2409 ||| IN
those  ||| S:2409 E:2415 ||| DT
treated  ||| S:2415 E:2423 ||| VBN
in  ||| S:2423 E:2426 ||| IN
the  ||| S:2426 E:2430 ||| DT
Hx-CD20-406  ||| S:2430 E:2442 ||| JJ
study ||| S:2442 E:2447 ||| NN
.  ||| S:2447 E:2449 ||| .
Further  ||| S:2449 E:2457 ||| JJ
uncertainty  ||| S:2457 E:2469 ||| NN
arose  ||| S:2469 E:2475 ||| VBD
regarding  ||| S:2475 E:2485 ||| VBG
the  ||| S:2485 E:2489 ||| DT
choice  ||| S:2489 E:2496 ||| NN
of  ||| S:2496 E:2499 ||| IN
utilities ||| S:2499 E:2508 ||| NNS
,  ||| S:2508 E:2510 ||| ,
the  ||| S:2510 E:2514 ||| DT
omission  ||| S:2514 E:2523 ||| NN
of  ||| S:2523 E:2526 ||| IN
17p  ||| S:2526 E:2530 ||| NNP
and  ||| S:2530 E:2534 ||| CC
11q  ||| S:2534 E:2538 ||| CD
chromosomal  ||| S:2538 E:2550 ||| CD
deletions  ||| S:2550 E:2560 ||| NNS
as  ||| S:2560 E:2563 ||| IN
factors  ||| S:2563 E:2571 ||| NNS
in  ||| S:2571 E:2574 ||| IN
the  ||| S:2574 E:2578 ||| DT
Cox  ||| S:2578 E:2582 ||| NNP
proportional  ||| S:2582 E:2595 ||| VBD
hazards  ||| S:2595 E:2603 ||| JJ
models  ||| S:2603 E:2610 ||| NNS
for  ||| S:2610 E:2614 ||| IN
PFS  ||| S:2614 E:2618 ||| NNP
and  ||| S:2618 E:2622 ||| CC
OS ||| S:2622 E:2624 ||| NNP
,  ||| S:2624 E:2626 ||| ,
and  ||| S:2626 E:2630 ||| CC
the  ||| S:2630 E:2634 ||| DT
omission  ||| S:2634 E:2643 ||| NN
of  ||| S:2643 E:2646 ||| IN
the  ||| S:2646 E:2650 ||| DT
costs  ||| S:2650 E:2656 ||| NNS
of  ||| S:2656 E:2659 ||| IN
drugs  ||| S:2659 E:2665 ||| NNS
in  ||| S:2665 E:2668 ||| IN
progressive  ||| S:2668 E:2680 ||| JJ
disease ||| S:2680 E:2687 ||| NN
.  ||| S:2687 E:2689 ||| .
It  ||| S:2689 E:2692 ||| PRP
was  ||| S:2692 E:2696 ||| VBD
felt  ||| S:2696 E:2701 ||| VBN
that  ||| S:2701 E:2706 ||| IN
these  ||| S:2706 E:2712 ||| DT
factors  ||| S:2712 E:2720 ||| NNS
biased  ||| S:2720 E:2727 ||| VBP
cost-effectiveness  ||| S:2727 E:2746 ||| JJ
in  ||| S:2746 E:2749 ||| IN
favour  ||| S:2749 E:2756 ||| NN
of  ||| S:2756 E:2759 ||| IN
ofatumumab ||| S:2759 E:2769 ||| NN
.  ||| S:2769 E:2771 ||| .
When  ||| S:2771 E:2776 ||| WRB
revisions  ||| S:2776 E:2786 ||| NNS
were  ||| S:2786 E:2791 ||| VBD
made  ||| S:2791 E:2796 ||| VBN
to  ||| S:2796 E:2799 ||| TO
the  ||| S:2799 E:2803 ||| DT
assumptions  ||| S:2803 E:2815 ||| NNS
in  ||| S:2815 E:2818 ||| IN
the  ||| S:2818 E:2822 ||| DT
model  ||| S:2822 E:2828 ||| NN
based  ||| S:2828 E:2834 ||| VBN
on  ||| S:2834 E:2837 ||| IN
the  ||| S:2837 E:2841 ||| DT
ERG ||| S:2841 E:2844 ||| NNP
's  ||| S:2844 E:2847 ||| POS
review  ||| S:2847 E:2854 ||| NN
of  ||| S:2854 E:2857 ||| IN
the  ||| S:2857 E:2861 ||| DT
published  ||| S:2861 E:2871 ||| VBN
and  ||| S:2871 E:2875 ||| CC
submitted  ||| S:2875 E:2885 ||| VBN
evidence ||| S:2885 E:2893 ||| NN
,  ||| S:2893 E:2895 ||| ,
the  ||| S:2895 E:2899 ||| DT
revised  ||| S:2899 E:2907 ||| JJ
base-case  ||| S:2907 E:2917 ||| JJ
incremental  ||| S:2917 E:2929 ||| JJ
cost-effectiveness  ||| S:2929 E:2948 ||| JJ
ratio  ||| S:2948 E:2954 ||| NN
for  ||| S:2954 E:2958 ||| IN
ofatumumab  ||| S:2958 E:2969 ||| NN
increased  ||| S:2969 E:2979 ||| VBD
to  ||| S:2979 E:2982 ||| TO
£  ||| S:2982 E:2984 ||| CD
81,500  ||| S:2984 E:2991 ||| CD
per  ||| S:2991 E:2995 ||| IN
quality-adjusted  ||| S:2995 E:3012 ||| JJ
life-year ||| S:3012 E:3021 ||| NN
.  ||| S:3021 E:3023 ||| .
The  ||| S:3023 E:3027 ||| DT
final  ||| S:3027 E:3033 ||| JJ
appraisal  ||| S:3033 E:3043 ||| NN
determination  ||| S:3043 E:3057 ||| NN
was  ||| S:3057 E:3061 ||| VBD
issued  ||| S:3061 E:3068 ||| VBN
by  ||| S:3068 E:3071 ||| IN
NICE  ||| S:3071 E:3076 ||| NNP
in  ||| S:3076 E:3079 ||| IN
September  ||| S:3079 E:3089 ||| NNP
2010  ||| S:3089 E:3094 ||| CD
( ||| S:3094 E:3095 ||| -LRB-
www.nice.org.uk ||| S:3095 E:3110 ||| FW
/ ||| S:3110 E:3111 ||| FW
nicemedia ||| S:3111 E:3120 ||| FW
/ ||| S:3120 E:3121 ||| FW
live ||| S:3121 E:3125 ||| JJ
/ ||| S:3125 E:3126 ||| CD
12264 ||| S:3126 E:3131 ||| CD
/ ||| S:3131 E:3132 ||| CD
50758 ||| S:3132 E:3137 ||| CD
/ ||| S:3137 E:3138 ||| CD
50758.pdf ||| S:3138 E:3147 ||| CD
) ||| S:3147 E:3148 ||| -RRB-
.  ||| S:3148 E:3150 ||| .
